Erasca
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
53 of 56
Similar slides by Erasca
See diffirences between slides (animation)
Investor Presentation
January 2024
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Investor Presentation
August 2023
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
IPO
July 2021
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Related slides by other companies
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase | RenovoRx
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase median overall survival gem alone | RenovoRx
ATAI
Investor Presentation
March 2023
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
ATAI
Investor Presentation
March 2023
achieved and expected milestones phase data phase data phase first subject dosed phase data anorexia key achievements to date phase data phase data initiation of clinical programs phase data phase a data phase data phase data phase data summer phase study data in cash as of plus access to up to an additional from term loan facility provides runway expected into we expect deliver several meaningful anticipated across our through with | ATAI
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
August 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights